Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Diab

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
Nature Medicine|April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim resultsIsabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Journal of Investigative Dermatology|August 23, 2014
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaAlan E Siroy, Genevieve M Boland, Denái R Milton, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Nature Medicine|April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim resultsIsabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Journal of Investigative Dermatology|August 23, 2014
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaAlan E Siroy, Genevieve M Boland, Denái R Milton, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Pageof 14